Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Marseille
Clinical trial register · France

Clinical Trials in Marseille, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Assistance Publique Hopitaux De Marseille91 AstraZeneca58 Institut Paoli-Calmettes40 Merck Sharp & Dohme LLC37 Novartis Pharmaceuticals36 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Marseille

58 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
2,800
Boulogne-sur-Mer, Caen, Cherbourg, Colmar, La Roche-sur-Yon, Le Mans, Marseille, Nîmes
2026-09-01
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Bron, Marseille, Montpellier, Nantes, Paris, Pessac, Suresnes
2026-07-24
Active, closed
AstraZeneca
Phase 2
326
Créteil, Marseille, Rennes, Toulouse
2026-06-11
Recruiting
AstraZeneca
Phase 3
59
Aix-en-Provence, Brest, Colmar, Gleizé, Grenoble, Lyon, Marseille, Montpellier
2026-05-05
Recruiting
AstraZeneca
Phase 3
245
Clermont-Ferrand, Lyon, Marseille, Paris, Pessac, Saint-Denis, Saint-Pierre, Toulon
2026-04-13
Recruiting
AstraZeneca
Phase 3
2,130
Bordeaux, Caen, Lyon, Marseille, Rennes, Villejuif
2026-02-03
Recruiting
AstraZeneca
Phase 3
1,100
Clichy, Grenoble, Marseille, Vandœuvre-lès-Nancy
2025-12-04
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bordeaux, Dijon, Limoges, Marseille, Nantes, Nice, Paris
2025-11-24
Recruiting
AstraZeneca
Phase 2
435
Brest, Créteil, Marseille, Montpellier, Paris, Pessac, Strasbourg, Toulouse
2025-11-06
Recruiting
AstraZeneca
Phase 3
400
Boulogne-Billancourt, Lyon, Marseille, Saint-Herblain, Toulouse
2025-10-31
Recruiting
AstraZeneca
Phase 3
700
Angers, Bordeaux, Caen, Clermont-Ferrand, Le Mans, Marseille, Montpellier, Nice
2025-08-06
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Bron, Dijon, Marseille, Paris, Saint-Herblain
2025-06-10
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Angers, Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier
2025-05-15
Recruiting
AstraZeneca
Phase 2
540
Brest, Créteil, Lyon, Marseille, Pessac, Strasbourg, Suresnes
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Brest, Lyon, Marseille, Montpellier, Paris, Pessac, Saint-Herblain
2025-03-25
Recruiting
AstraZeneca
Phase 3
840
Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Poitiers, Rennes
2025-03-01
Active, closed
AstraZeneca
Phase 3
181
Le Kremlin-Bicêtre, Marseille, Nantes, Pierre-Bénite, Poitiers, Toulouse
2024-12-03
Active, closed
AstraZeneca
Phase 3
310
Créteil, La Tronche, Lyon, Marseille, Montpellier, Strasbourg
2024-09-30
Recruiting
AstraZeneca
Phase 3
620
Brest, Clichy, Dijon, Lille, Lyon, Marseille, Montpellier, Pessac
2024-08-12
Recruiting
AstraZeneca
Phase 3
788
Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain
2024-08-01
Recruiting
AstraZeneca
Phase 3
582
Angers, Marseille, Paris, Strasbourg
2024-04-29
Active, closed
AstraZeneca
Phase 2
142
La Tronche, Marseille, Montpellier, Mulhouse, Paris, Pessac, Poitiers, Toulouse
2024-02-22
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Caen, Marseille, Nantes, Paris, Pierre-Bénite, Toulouse
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Strasbourg, Grenoble, St-Malo, Mulhouse, Boulogne-sur-Mer, Poitiers, Avignon, Marseille
2023-12-20
Active, closed
AstraZeneca
Phase 3
760
Marseille, Montpellier, Pessac, Rennes, Strasbourg, Toulouse, Villejuif
2023-12-04
Active, closed
AstraZeneca
Phase 3
1,902
Avignon, Bayonne, Caen, Clermont-Ferrand, Limoges, Marseille, Montpellier, Nice
2023-11-14
Active, closed
AstraZeneca
Phase 3
863
Brest, Créteil, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris
2023-11-09
Active, closed
AstraZeneca
Phase 3
895
Angers, Avignon, Bayonne, Bordeaux, Caen, Lille, Limoges, Marseille
2023-10-24
Recruiting
AstraZeneca
Phase 3
231
Brest, Bron, Créteil, Marseille, Paris, Rouen, Vandœuvre-lès-Nancy
2023-08-24
Active, closed
AstraZeneca
Phase 3
111
Bobigny, Clichy, Créteil, Marseille, Rennes
2023-06-27
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Marseille, Rennes, Villejuif
2022-12-21
Recruiting
AstraZeneca
Phase 2
454
Bordeaux, Lyon, Marseille, Suresnes
2022-09-06
Active, closed
AstraZeneca
Phase 2
194
Bobigny, Boulogne-Billancourt, Marseille, Paris, Pau, Pierre-Bénite, Poitiers, Vandœuvre-lès-Nancy
2022-08-11
Active, closed
AstraZeneca
Phase 3
341
Bobigny, Brest, Créteil, Dijon, Marseille, Paris, Poitiers, Rennes
2022-08-03
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes
2022-04-19
Active, closed
AstraZeneca
Phase 3
363
Aurillac, Bordeaux, Marseille, Paris, Strasbourg, Toulouse
2022-02-15
Active, closed
AstraZeneca
Phase 3
1,051
Avignon, Besançon, Bordeaux, Clermont-Ferrand, Créteil, Lorient, Marseille, Montpellier
2022-02-07
Active, closed
AstraZeneca
Phase 3
454
Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
712
Amiens, Bayonne, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nice
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Avignon, Brest, Clermont-Ferrand, Dijon, Limoges, Lorient, Lyon, Marseille
2021-06-30
Active, closed
AstraZeneca
Phase 3
370
Avignon, Bordeaux, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Strasbourg
2020-10-02
Active, closed
AstraZeneca
Phase 3
866
Avignon, Besançon, Bordeaux, Brest, Caen, Dijon, Le Mans, Marseille
2020-07-24
Active, closed
AstraZeneca
Phase 3
1,012
Besançon, Bordeaux, Marseille, Montpellier, Nice, Paris, Pierre-Bénite, Quimper
2020-07-13
Active, closed
AstraZeneca
Phase 3
140
Dijon, Marseille, Montpellier, Nantes, Paris, Suresnes, Toulouse
2019-10-29
Active, closed
AstraZeneca
Phase 3
923
Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif
2019-06-25
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Lille, Marseille, Paris
2019-03-07
Active, closed
AstraZeneca
Phase 2
367
Dijon, Marseille, Nantes, Paris, Rennes
2019-01-09
Active, closed
AstraZeneca
Phase 3
1,407
Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain
2019-01-04
Active, closed
AstraZeneca
Phase 3
1,018
Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier
2018-03-07
Active, closed
AstraZeneca
Phase 3
1,324
Clichy, Lille, Marseille, Montpellier, Nancy, Nantes, Nice, Pessac
2017-10-11
Active, closed
AstraZeneca
Phase 1
117
Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
2016-12-28
Active, closed
AstraZeneca
Phase 1/2
264
Bordeaux, Caen, Clermont-Ferrand, Dijon, Marseille, Nantes, Paris, Pierre Benit Cedex
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Active, closed
AstraZeneca
Phase 3
1,118
Bordeaux, Brest, Créteil, Lille, Lyon, Marseille
2015-07-21
Active, closed
AstraZeneca
Phase 3
510
Brest, Caen, Clermont-Ferrand, Dijon, Lille, Marseille, Paris, Pierre-Bénite
2013-09-25
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/marseille

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Marseille that also match the filters currently applied.

How many clinical trials are recruiting in Marseille?

21 of the 58 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 36 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Marseille), 58 studies
PhaseStudiesRecruitingShare
Phase 3411470.7%
Phase 29415.5%
Phase 1/2426.9%
Observational213.4%
Phase 1203.4%

Most active sponsors

Lead sponsors with the most studies (Marseille)
Lead sponsorStudiesRecruiting
AstraZeneca5821
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.